Other (Income)/Deductions—Net - Schedule of Impaired Intangible Assets (Details) $ in Millions	3 Months Ended
	Mar. 30, 2025 USD ($)
Finite-Lived Intangible Assets [Line Items]
Total	$ 0	[1]
Impairment	224
Indefinite-lived licensing agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived licensing agreement	0	[1],[2]
Impairment	210	[2]
Developed technology rights [Member]
Finite-Lived Intangible Assets [Line Items]
Developed technology rights	0	[1],[2]
Impairment	14	[2]
Level 1 [Member]
Finite-Lived Intangible Assets [Line Items]
Total	0	[1]
Level 1 [Member] | Developed technology rights [Member]
Finite-Lived Intangible Assets [Line Items]
Developed technology rights	0	[1],[2]
Level 2 [Member]
Finite-Lived Intangible Assets [Line Items]
Total	0	[1]
Level 2 [Member] | Developed technology rights [Member]
Finite-Lived Intangible Assets [Line Items]
Developed technology rights	0	[1],[2]
Level 3 [Member]
Finite-Lived Intangible Assets [Line Items]
Total	0	[1]
Level 3 [Member] | Developed technology rights [Member]
Finite-Lived Intangible Assets [Line Items]
Developed technology rights	$ 0	[1],[2]

[1] The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also Note 1E in our 2024 Form 10-K.

[2] Reflects intangible assets written down to fair value in 2025. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.